Dysregulated Ryanodine Receptors Mediate Cellular Toxicity: Restoration of Normal Phenotype by FKBP12.6
Overview
Affiliations
Ca2+ homeostasis is a vital cellular control mechanism in which Ca2+ release from intracellular stores plays a central role. Ryanodine receptor (RyR)-mediated Ca2+ release is a key modulator of Ca2+ homeostasis, and the defective regulation of RyR is pathogenic. However, the molecular events underlying RyR-mediated pathology remain undefined. Cells stably expressing recombinant human RyR2 (Chinese hamster ovary cells, CHOhRyR2) had similar resting cytoplasmic Ca2+ levels ([Ca2+]c) to wild-type CHO cells (CHOWT) but exhibited increased cytoplasmic Ca2+ flux associated with decreased cell viability and proliferation. Intracellular Ca2+ flux increased with human RyR2 (hRyR2) expression levels and determined the extent of phenotypic modulation. Co-expression of FKBP12.6, but not FKBP12, or incubation of cells with ryanodine suppressed intracellular Ca2+ flux and restored normal cell viability and proliferation. Restoration of normal phenotype was independent of the status of resting [Ca2+]c or ER Ca2+ load. Heparin inhibition of endogenous inositol trisphosphate receptors (IP3R) had little effect on intracellular Ca2+ handling or viability. However, purinergic stimulation of endogenous IP3R resulted in apoptotic cell death mediated by hRyR2 suggesting functional interaction occurred between IP3R and hRyR2 Ca2+ release channels. These data demonstrate that defective regulation of RyR causes altered cellular phenotype via profound perturbations in intracellular Ca2+ signaling and highlight a key modulatory role of FKBP12.6 in hRyR2 Ca2+ channel function.
Jones A, Edwards D, Cummins M, Williams A, George C Front Cell Dev Biol. 2016; 3:89.
PMID: 26793710 PMC: 4710702. DOI: 10.3389/fcell.2015.00089.
Lewis K, Silvester N, Barberini-Jammaers S, Mason S, Marsh S, Lipka M J Biomol Screen. 2014; 20(3):330-40.
PMID: 25367900 PMC: 4361473. DOI: 10.1177/1087057114557232.
Calcium cycling proteins and heart failure: mechanisms and therapeutics.
Marks A J Clin Invest. 2013; 123(1):46-52.
PMID: 23281409 PMC: 3533269. DOI: 10.1172/JCI62834.
Phillips S, Yu Y, Rossbach A, Nomikos M, Vassilakopoulou V, Livaniou E Biochem J. 2011; 438(3):545-53.
PMID: 21692749 PMC: 3195308. DOI: 10.1042/BJ20101581.
Guo T, Cornea R, Huke S, Camors E, Yang Y, Picht E Circ Res. 2010; 106(11):1743-52.
PMID: 20431056 PMC: 2895429. DOI: 10.1161/CIRCRESAHA.110.219816.